Immediate second resection versus restage transurethral resection of bladder tumor: A prospective randomized clinical trial (IMMERSE trial)

May 11, 2025 by in ONCOLOGY Comments Off on Immediate second resection versus restage transurethral resection of bladder tumor: A prospective randomized clinical trial (IMMERSE trial)

Highlights • Detrusor muscle sampling rates are significantly higher in patients undergoing immediate second resection than standard TURBT (97% vs. 66%). • There is a high rate of recurrence in…

read more

The clinical relevance of cut-off percentage for high-grade urothelial carcinoma within low-grade urothelial carcinoma: A determining factor?

May 11, 2025 by in ONCOLOGY Comments Off on The clinical relevance of cut-off percentage for high-grade urothelial carcinoma within low-grade urothelial carcinoma: A determining factor?

Abstract Aims The aim of the study was to analyze the cut-off value for the percentage of the high-grade (HG) component that has clinical significance in urothelial carcinoma (UC). Material…

read more

Tumor location at trans-urethral resection is predictive of ipsilateral pelvic lymph-nodal metastases in patients undergoing radical cystectomy for bladder cancer

May 11, 2025 by in ONCOLOGY Comments Off on Tumor location at trans-urethral resection is predictive of ipsilateral pelvic lymph-nodal metastases in patients undergoing radical cystectomy for bladder cancer

Highlights • Tumor location at TURBT predicts ipsilateral lymph node metastases. • Right-sided tumors show more positive ipsilateral lymph nodes. • Left-sided tumors also predict increased ipsilateral node positivity. •…

read more

Pattern and risk factors of local recurrence and intravesical recurrence after segmental ureterectomy for upper tract urothelial carcinoma

May 11, 2025 by in ONCOLOGY Comments Off on Pattern and risk factors of local recurrence and intravesical recurrence after segmental ureterectomy for upper tract urothelial carcinoma

Highlights • Segmental ureterectomy was feasible for selected ureteral cancer patients. • Segmental ureterectomy faced a considerable risk of local recurrence and intravesical recurrence. • G3 and lymphatic vascular infiltration…

read more

Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan

May 11, 2025 by in ONCOLOGY Comments Off on Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan

Highlights • A study in patients with unresectable or metastatic urothelial carcinoma (mUC). • Half of patients received cisplatin-based regimens as first-line therapy. • After 2017, 58.2% of patients received…

read more

Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)

May 11, 2025 by in ONCOLOGY Comments Off on Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial carcinoma: Results from a phase II single-arm study (PIVOT-10)

Highlights • Bempegaldesleukin is a pegylated interleukin-2 cytokine. • This phase 2 study was conducted in patients previously untreated advanced or metastatic urothelial carcinoma and low PD-L1 expression. • The…

read more

Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns

May 11, 2025 by in ONCOLOGY Comments Off on Guidelines versus real-world data in metastatic bladder cancer: A population-based study on first-line chemotherapy treatment patterns

Abstract Background For patients with metastatic bladder cancer (mBC) palliative chemotherapy is one of the main treatment options. Real-world insights into outcomes are available, but a comprehensive overview of specific…

read more

Critical care therapy and in-hospital mortality after radical nephroureterectomy for nonmetastatic upper urinary tract carcinoma

May 11, 2025 by in ONCOLOGY Comments Off on Critical care therapy and in-hospital mortality after radical nephroureterectomy for nonmetastatic upper urinary tract carcinoma

Highlights • Critical care therapy represents a 5- to 6-fold multiple of in-hospital mortality rate. Moreover, critical care therapy very closely reflects in-hospital mortality rate changes that occurred over time…

read more

Is ipsilateral systematic biopsy combined with targeted biopsy the optimal substitute for bilateral systematic biopsy combined with targeted biopsy: A systematic review and meta-analysis

May 11, 2025 by in ONCOLOGY Comments Off on Is ipsilateral systematic biopsy combined with targeted biopsy the optimal substitute for bilateral systematic biopsy combined with targeted biopsy: A systematic review and meta-analysis

Highlights • The standard prostate biopsy method results in overdiagnosis and overtreatment. • ips-SB+TB can be an alternative for detecting prostate cancer (PCa). • Ips-SB+TB has comparable efficiency in detecting…

read more
Get Clinical Tree app for offline access